Protocol Ledger

NCT03293524 · Phase III · COMPLETED

Efficacy & Safety Study of Bilateral IVT Injection of GS010 in LHON Subjects Due to the ND4 Mutation for up to 1 Year

Interventional Phase III clinical trial protocol NCT03293524 sponsored by GenSight Biologics in Neurology, Psychiatry, and Pain, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2018-03-12 Enrollment: 98 participants (ACTUAL) Federal Source: clinicaltrials.gov/study/NCT03293524
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)98 participants (ACTUAL)
Disclosed U.S. Hospital Campuses vs Median (6 sites)4 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT03293524
Protocol FieldVerified Registry Value
NCT IdentifierNCT03293524
Consolidated Lead SponsorGenSight Biologics
Therapeutic Condition CohortNeurology, Psychiatry, and Pain
Clinical Trial PhasePhase III
Overall Recruitment StatusCOMPLETED
Registered Enrollment98 participants (ACTUAL)
Registered Start Date2018-03-12
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Search related sites and sponsors in the Interactive Directory, explore Neurology, Psychiatry, and Pain Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI